Han Kyu Chae, Nayoung Suh, Myong Jin Jang, Yu Seon Kim, Bo Hyun Kim, Joomin Aum, Ha Chul Shin, Dalsan You, Bumsik Hong, Hyung Keun Park, Choung-Soo Kim
{"title":"人骨髓间充质干细胞注射途径和剂量对慢性肾病大鼠模型的疗效和安全性。","authors":"Han Kyu Chae, Nayoung Suh, Myong Jin Jang, Yu Seon Kim, Bo Hyun Kim, Joomin Aum, Ha Chul Shin, Dalsan You, Bumsik Hong, Hyung Keun Park, Choung-Soo Kim","doi":"10.15283/ijsc21146","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>We compared the efficacy and safety of human bone marrow-derived mesenchymal stem cells (hBMSC), delivered at different doses and via different injection routes in an animal model of chronic kidney disease.</p><p><strong>Methods and results: </strong>A total of ninety 12-week-old rats underwent 5/6 nephrectomy and randomized among nine groups: sham, renal artery control (RA-C), tail vein control (TV-C), renal artery low dose (RA-LD) (0.5×10<sup>6</sup> cells), renal artery moderate dose (RA-MD) (1.0×10<sup>6</sup> cells), renal artery high dose (RA-HD) (2.0×10<sup>6</sup> cells), tail vein low dose (TV-LD) (0.5×10<sup>6</sup> cells), tail vein moderate dose (TV-MD) (1.0×10<sup>6</sup> cells), and tail vein high dose (TV-HD) (2.0×10<sup>6</sup> cells). Renal function and mortality of rats were evaluated after hBMSC injection. Serum blood urea nitrogen was significantly lower in the TV-HD group at 2 weeks (p<0.01), 16 weeks (p<0.05), and 24 weeks (p<0.01) than in the TV-C group, as determined by one-way ANOVA. Serum creatinine was significantly lower in the TV-HD group at 24 weeks (p<0.05). At 8 weeks, creatinine clearance was significantly higher in the TV-MD and TV-HD groups (p<0.01, p<0.05) than in the TV-C group. In the safety evaluation, we observed no significant difference among the groups.</p><p><strong>Conclusions: </strong>Our findings confirm the efficacy and safety of high dose (2×10<sup>6</sup> cells) injection of hBMSC via the tail vein.</p>","PeriodicalId":14392,"journal":{"name":"International journal of stem cells","volume":"16 1","pages":"66-77"},"PeriodicalIF":2.5000,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/ca/ijsc-16-1-66.PMC9978839.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Human Bone Marrow-Derived Mesenchymal Stem Cells according to Injection Route and Dose in a Chronic Kidney Disease Rat Model.\",\"authors\":\"Han Kyu Chae, Nayoung Suh, Myong Jin Jang, Yu Seon Kim, Bo Hyun Kim, Joomin Aum, Ha Chul Shin, Dalsan You, Bumsik Hong, Hyung Keun Park, Choung-Soo Kim\",\"doi\":\"10.15283/ijsc21146\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>We compared the efficacy and safety of human bone marrow-derived mesenchymal stem cells (hBMSC), delivered at different doses and via different injection routes in an animal model of chronic kidney disease.</p><p><strong>Methods and results: </strong>A total of ninety 12-week-old rats underwent 5/6 nephrectomy and randomized among nine groups: sham, renal artery control (RA-C), tail vein control (TV-C), renal artery low dose (RA-LD) (0.5×10<sup>6</sup> cells), renal artery moderate dose (RA-MD) (1.0×10<sup>6</sup> cells), renal artery high dose (RA-HD) (2.0×10<sup>6</sup> cells), tail vein low dose (TV-LD) (0.5×10<sup>6</sup> cells), tail vein moderate dose (TV-MD) (1.0×10<sup>6</sup> cells), and tail vein high dose (TV-HD) (2.0×10<sup>6</sup> cells). Renal function and mortality of rats were evaluated after hBMSC injection. Serum blood urea nitrogen was significantly lower in the TV-HD group at 2 weeks (p<0.01), 16 weeks (p<0.05), and 24 weeks (p<0.01) than in the TV-C group, as determined by one-way ANOVA. Serum creatinine was significantly lower in the TV-HD group at 24 weeks (p<0.05). At 8 weeks, creatinine clearance was significantly higher in the TV-MD and TV-HD groups (p<0.01, p<0.05) than in the TV-C group. In the safety evaluation, we observed no significant difference among the groups.</p><p><strong>Conclusions: </strong>Our findings confirm the efficacy and safety of high dose (2×10<sup>6</sup> cells) injection of hBMSC via the tail vein.</p>\",\"PeriodicalId\":14392,\"journal\":{\"name\":\"International journal of stem cells\",\"volume\":\"16 1\",\"pages\":\"66-77\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2023-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/ca/ijsc-16-1-66.PMC9978839.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of stem cells\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15283/ijsc21146\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of stem cells","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15283/ijsc21146","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
Efficacy and Safety of Human Bone Marrow-Derived Mesenchymal Stem Cells according to Injection Route and Dose in a Chronic Kidney Disease Rat Model.
Background and objectives: We compared the efficacy and safety of human bone marrow-derived mesenchymal stem cells (hBMSC), delivered at different doses and via different injection routes in an animal model of chronic kidney disease.
Methods and results: A total of ninety 12-week-old rats underwent 5/6 nephrectomy and randomized among nine groups: sham, renal artery control (RA-C), tail vein control (TV-C), renal artery low dose (RA-LD) (0.5×106 cells), renal artery moderate dose (RA-MD) (1.0×106 cells), renal artery high dose (RA-HD) (2.0×106 cells), tail vein low dose (TV-LD) (0.5×106 cells), tail vein moderate dose (TV-MD) (1.0×106 cells), and tail vein high dose (TV-HD) (2.0×106 cells). Renal function and mortality of rats were evaluated after hBMSC injection. Serum blood urea nitrogen was significantly lower in the TV-HD group at 2 weeks (p<0.01), 16 weeks (p<0.05), and 24 weeks (p<0.01) than in the TV-C group, as determined by one-way ANOVA. Serum creatinine was significantly lower in the TV-HD group at 24 weeks (p<0.05). At 8 weeks, creatinine clearance was significantly higher in the TV-MD and TV-HD groups (p<0.01, p<0.05) than in the TV-C group. In the safety evaluation, we observed no significant difference among the groups.
Conclusions: Our findings confirm the efficacy and safety of high dose (2×106 cells) injection of hBMSC via the tail vein.
期刊介绍：
International Journal of Stem Cells (Int J Stem Cells), a peer-reviewed open access journal, principally aims to provide a forum for investigators in the field of stem cell biology to present their research findings and share their visions and opinions. Int J Stem Cells covers all aspects of stem cell biology including basic, clinical and translational research on genetics, biochemistry, and physiology of various types of stem cells including embryonic, adult and induced stem cells. Reports on epigenetics, genomics, proteomics, metabolomics of stem cells are welcome as well. Int J Stem Cells also publishes review articles, technical reports and treatise on ethical issues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
